The Committee for Human Medicinal Products (CHMP) at the European Medicines Agency (EMA) is currently concerned with a risk evaluation of sibutramin. The re-evaluation was prompted by the preliminary results of a large long-time study conducted in several countries (SCOUT study) with about 10,000 substantially overweight patients.

risk information - full text (available in German only)